We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Trecento Diagnostics, with the help of a molecular testing system complete, they are now ready to launch a patent-pending collection device named HygieCatch®. It is a non-invasive, needle-free examination, in the vet practice providing DNA extraction from urine onsite with a report within 40 minutes of extraction of the sample. The company has identified partners in the UAE and US and is also in early-stage discussions with UK vet practices.  Furthermore, for the purpose of commercialisation of HygieCatch & the technology used, alongside addition of new tests including Lyme disease the company is planning to raise its capital.  
days to go: Expired investment: £167,910
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go: Expired investment: £250,000
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
days to go: Expired investment: £99,000
Tourniglo is a company that has come up with a unique two in one emergency tourniquet with a built-in torch. The innovation was driven by an identified need within the emergency services to provide an immediately available light source in dim-lighted areas when undertaking a patient or casualty eye examination as well as for military and close protection staff who might need to inject intravenous medication in rural areas. The global tourniquet systems market is expected to reach half a billion US dollars by 2025. The company aims to launch the production of its first product. Additionally, Tourniglo has been featured on the BBC website and has won various medals at international events, including a 'Gold Medal' at the World Invention Awards. The company requires investment to set-up manufacturing, packaging and distribution, and grow sales for the first year of commercialisation.
days to go: Expired investment: £21,414
Cell Guidance Systems is developing a technology called PODS (Polyhedrin Delivery System) PODS allow them to deliver therapeutic proteins accurately and over long periods of time. PODS enable proteins to treat diseases, such as Parkinson’s disease and osteoarthritis.
days to go: Expired investment: £836,370
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).

Pitch Rated

75%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £311,690
Infections can be reduced and patient quality of life can be improved by using antimicrobial wound care materials developed by Pertinax. In vitro studies have already been performed using the company's development across multiple applications.
days to go: Expired investment: £616,916
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their health where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go: Expired investment: £737,480
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph